{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T00:17:20Z","timestamp":1794788240070,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":111,"publisher":"Springer US","isbn-type":[{"value":"9781071640029","type":"print"},{"value":"9781071640036","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4003-6_12","type":"book-chapter","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T06:02:36Z","timestamp":1727071356000},"page":"249-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adverse Outcome Pathways Mechanistically Describing Hepatotoxicity"],"prefix":"10.1007","author":[{"given":"Ellen","family":"Callewaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Louisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Sanz-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vinken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/toxsci\/kfac039","volume":"187","author":"GP Daston","year":"2022","unstructured":"Daston GP, Mahony C, Thomas RS et al (2022) Assessing safety without animal testing: the road ahead. Toxicol Sci 187:214\u2013218","journal-title":"Toxicol Sci"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/liv.14800","volume":"41","author":"E Gijbels","year":"2021","unstructured":"Gijbels E, Pieters A, De Muynck K et al (2021) Rodent models of cholestatic liver disease: a practical guide for translational research. Liver Int 41:656\u2013682","journal-title":"Liver Int"},{"key":"12_CR3","unstructured":"U.S. (2018) Strategic plan to promote the development and implementation of alternative test methods within the TSCA program, Environmental Protection Agency, United States"},{"key":"12_CR4","volume":"17","author":"S Bronzwaer","year":"2019","unstructured":"Bronzwaer S, Kass G, Robinson T et al (2019) Food safety regulatory research needs 2030. EFSA J 17:e170622","journal-title":"EFSA J"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxres\/tfac087","volume":"12","author":"S Brescia","year":"2023","unstructured":"Brescia S, Alexander-White C, Li H et al (2023) Risk assessment in the 21st century: where are we heading? Toxicol Res (Camb) 12:1\u201311","journal-title":"Toxicol Res (Camb)"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cotox.2018.03.004","volume":"9","author":"GT Ankley","year":"2018","unstructured":"Ankley GT, Edwards SW (2018) The adverse outcome pathway: a multifaceted framework supporting 21st century toxicology. Curr Opin Toxicol 9:1\u20137","journal-title":"Curr Opin Toxicol"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/jat.3165","volume":"35","author":"N Burden","year":"2015","unstructured":"Burden N, Sewell F, Andersen ME et al (2015) Adverse outcome pathways can drive non-animal approaches for safety assessment. J Appl Toxicol 35:971\u2013975","journal-title":"J Appl Toxicol"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/etc.3805","volume":"36","author":"CA LaLone","year":"2017","unstructured":"LaLone CA, Ankley GT, Belanger SE et al (2017) Advancing the adverse outcome pathway framework-an international horizon scanning approach. Environ Toxicol Chem 36:1411\u20131421","journal-title":"Environ Toxicol Chem"},{"key":"12_CR9","unstructured":"Kalra A, Yetiskul E, Wehrle CJ, et al (2023) Physiology, liver. In: StatPearls, StatPearls Publishing, Treasure Island (FL)"},{"key":"12_CR10","unstructured":"AOP-Wiki, https:\/\/aopwiki.org\/"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/etc.34","volume":"29","author":"GT Ankley","year":"2010","unstructured":"Ankley GT, Bennett RS, Erickson RJ et al (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29:730\u2013741","journal-title":"Environ Toxicol Chem"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/toxsci\/kfu199","volume":"142","author":"DL Villeneuve","year":"2014","unstructured":"Villeneuve DL, Crump D, Garcia-Reyero N et al (2014) Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol Sci 142:312\u2013320","journal-title":"Toxicol Sci"},{"key":"12_CR13","unstructured":"Villeneuve D, Meek B, Viviani B et al AOP developers handbook. https:\/\/aopwiki.org\/handbooks\/3"},{"key":"12_CR14","doi-asserted-by":"publisher","unstructured":"OECD (2018) Users\u2019 handbook supplement to the guidance document for developing and assessing adverse outcome pathways. OECD Series on Adverse Outcome Pathways, No. 1, OECD Publishing, Paris. https:\/\/doi.org\/10.1787\/5jlv1m9d1g32-en","DOI":"10.1787\/5jlv1m9d1g32-en"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/978-1-0716-1960-5_20","volume":"2425","author":"E Arnesdotter","year":"2022","unstructured":"Arnesdotter E, Gijbels E, Dos Santos RB et al (2022) Adverse outcome pathways as versatile tools in liver toxicity testing. Methods Mol Biol 2425:521\u2013535","journal-title":"Methods Mol Biol"},{"key":"12_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100195","volume":"21","author":"A Paini","year":"2022","unstructured":"Paini A, Campia I, Cronin MTD et al (2022) Towards a qAOP framework for predictive toxicology \u2013 linking data to decisions. Comput Toxicol 21:100195","journal-title":"Comput Toxicol"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/toxsci\/kfu200","volume":"142","author":"DL Villeneuve","year":"2014","unstructured":"Villeneuve DL, Crump D, Garcia-Reyero N et al (2014) Adverse outcome pathway development II: best practices. Toxicol Sci 142:321\u2013330","journal-title":"Toxicol Sci"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/etc.4125","volume":"37","author":"D Knapen","year":"2018","unstructured":"Knapen D, Angrish MM, Fortin MC et al (2018) Adverse outcome pathway networks I: development and applications. Environ Toxicol Chem 37:1723\u20131733","journal-title":"Environ Toxicol Chem"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/etc.4124","volume":"37","author":"DL Villeneuve","year":"2018","unstructured":"Villeneuve DL, Angrish MM, Fortin MC et al (2018) Adverse outcome pathway networks II: network analytics. Environ Toxicol Chem 37:1734\u20131748","journal-title":"Environ Toxicol Chem"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/toxsci\/kfz006","volume":"168","author":"NL Pollesch","year":"2019","unstructured":"Pollesch NL, Villeneuve DL, O\u2019Brien JM (2019) Extracting and benchmarking emerging adverse outcome pathway knowledge. Toxicol Sci 168:349\u2013364","journal-title":"Toxicol Sci"},{"key":"12_CR21","doi-asserted-by":"publisher","unstructured":"OECD (2021) Guidance document for the scientific review of adverse outcome pathways. OECD Series on testing and assessment, No. 344, OECD Publishing, Paris. https:\/\/doi.org\/10.1787\/a6bec14b-en","DOI":"10.1787\/a6bec14b-en"},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cotox.2019.02.006","volume":"18","author":"M Vinken","year":"2019","unstructured":"Vinken M (2019) Omics-based input and output in the development and use of adverse outcome pathways. Curr Opin Toxicol 18:8\u201312","journal-title":"Curr Opin Toxicol"},{"key":"12_CR23","volume":"7","author":"MPF Corradi","year":"2022","unstructured":"Corradi MPF, de Haan AM, Staumont B et al (2022) Natural language processing in toxicology: delineating adverse outcome pathways and guiding the application of new approach methodologies. Biomater Biosyst 7:100061","journal-title":"Biomater Biosyst"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-1-60327-194-3_16","volume":"593","author":"M Krallinger","year":"2010","unstructured":"Krallinger M, Leitner F, Valencia A (2010) Analysis of biological processes and diseases using text mining approaches. Methods Mol Biol 593:341\u2013382","journal-title":"Methods Mol Biol"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"1183824","DOI":"10.3389\/ftox.2023.1183824","volume":"5","author":"L Wiklund","year":"2023","unstructured":"Wiklund L, Caccia S, P\u00edpal M et al (2023) Development of a data-driven approach to adverse outcome pathway network generation: a case study on the EATS-modalities. Front Toxicol 5:1183824","journal-title":"Front Toxicol"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/bioinformatics\/btab750","volume":"38","author":"F Jornod","year":"2022","unstructured":"Jornod F, Jaylet T, Blaha L et al (2022) AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development. Bioinformatics 38:1173\u20131175","journal-title":"Bioinformatics"},{"key":"12_CR27","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295\u2013300","journal-title":"Proc R Soc Med"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jat.2949","volume":"34","author":"ME Meek","year":"2014","unstructured":"Meek ME, Boobis A, Cote I et al (2014) New developments in the evolution and application of the WHO\/IPCS framework on mode of action\/species concordance analysis. J Appl Toxicol 34:1\u201318","journal-title":"J Appl Toxicol"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.yrtph.2015.04.004","volume":"72","author":"RA Becker","year":"2015","unstructured":"Becker RA, Ankley GT, Edwards SW (2015) Increasing scientific confidence in adverse outcome pathways: application of tailored bradford-hill considerations for evaluating weight of evidence. Regul Toxicol Pharmacol 72:514\u2013537","journal-title":"Regul Toxicol Pharmacol"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.yrtph.2017.02.017","volume":"86","author":"RA Becker","year":"2017","unstructured":"Becker RA, Dellarco V, Seed J et al (2017) Quantitative weight of evidence to assess confidence in potential modes of action. Regul Toxicol Pharmacol 86:205\u2013220","journal-title":"Regul Toxicol Pharmacol"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/etc.4505","volume":"38","author":"EJ Perkins","year":"2019","unstructured":"Perkins EJ, Ashauer R, Burgoon L et al (2019) Building and applying quantitative adverse outcome pathway models for chemical Hazard and risk assessment. Environ Toxicol Chem 38:1850\u20131865","journal-title":"Environ Toxicol Chem"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00204-020-02774-7","volume":"94","author":"N Spinu","year":"2020","unstructured":"Spinu N, Cronin MTD, Enoch SJ et al (2020) Quantitative adverse outcome pathway (qAOP) models for toxicity prediction. Arch Toxicol 94:1497\u20131510","journal-title":"Arch Toxicol"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ieam.4348","volume":"17","author":"SJ Moe","year":"2021","unstructured":"Moe SJ, Wolf R, Xie L et al (2021) Quantification of an adverse outcome pathway network by Bayesian regression and Bayesian network modeling. Integr Environ Assess Manag 17:147\u2013164","journal-title":"Integr Environ Assess Manag"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/cld.894","volume":"15","author":"FQ Onofrio","year":"2020","unstructured":"Onofrio FQ, Hirschfield GM (2020) The pathophysiology of cholestasis and its relevance to clinical practice. Clin Liver Dis (Hoboken) 15:110\u2013114","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/toxsci\/kft177","volume":"136","author":"M Vinken","year":"2013","unstructured":"Vinken M, Landesmann B, Goumenou M et al (2013) Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol Sci 136:97\u2013106","journal-title":"Toxicol Sci"},{"key":"12_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2023.104465","volume":"145","author":"J Ertvelde","year":"2023","unstructured":"Ertvelde J, Verhoeven A, Maerten A et al (2023) Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach. J Biomed Inform 145:104465","journal-title":"J Biomed Inform"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1124\/dmd.116.071373","volume":"44","author":"MG Burbank","year":"2016","unstructured":"Burbank MG, Burban A, Sharanek A et al (2016) Early alterations of bile canaliculi dynamics and the rho kinase\/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis. Drug Metab Dispos 44:1780\u20131793","journal-title":"Drug Metab Dispos"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"bio058606","DOI":"10.1242\/bio.058606","volume":"10","author":"R Sonoi","year":"2021","unstructured":"Sonoi R, Hagihara Y (2021) Tight junction stabilization prevents HepaRG cell death in drug-induced intrahepatic cholestasis. Biol Open 10:bio058606","journal-title":"Biol Open"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/17425255.2014.884069","volume":"10","author":"M de Lima Toccafondo Vieira","year":"2014","unstructured":"de Lima Toccafondo Vieira M, Tagliati CA (2014) Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. Expert Opin Drug Metab Toxicol 10:581\u2013597","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"12_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.04.018","volume":"154","author":"A Jetter","year":"2020","unstructured":"Jetter A, Kullak-Ublick GA (2020) Drugs and hepatic transporters: a review. Pharmacol Res 154:104234","journal-title":"Pharmacol Res"},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.3390\/ijms24065823","volume":"24","author":"G Vitale","year":"2023","unstructured":"Vitale G, Mattiaccio A, Conti A et al (2023) Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis. Int J Mol Sci 24:5823","journal-title":"Int J Mol Sci"},{"key":"12_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087548","volume":"9","author":"E-I Lepist","year":"2014","unstructured":"Lepist E-I, Gillies H, Smith W et al (2014) Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS One 9:e87548","journal-title":"PLoS One"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00204-019-02437-2","volume":"93","author":"E Gijbels","year":"2019","unstructured":"Gijbels E, Vilas-Boas V, Deferm N et al (2019) Mechanisms and in vitro models of drug-induced cholestasis. Arch Toxicol 93:1169\u20131186","journal-title":"Arch Toxicol"},{"key":"12_CR44","first-page":"346","volume":"32","author":"M-M Tiao","year":"2009","unstructured":"Tiao M-M, Lin T-K, Wang P-W et al (2009) The role of mitochondria in cholestatic liver injury. Chang Gung Med J 32:346\u2013353","journal-title":"Chang Gung Med J"},{"key":"12_CR45","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.3390\/ijms19113630","volume":"19","author":"M Garcia","year":"2018","unstructured":"Garcia M, Thirouard L, Sed\u00e8s L et al (2018) Nuclear receptor metabolism of bile acids and Xenobiotics: a coordinated detoxification system with impact on health and diseases. Int J Mol Sci 19:3630","journal-title":"Int J Mol Sci"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1021\/mp060010s","volume":"3","author":"G Zollner","year":"2006","unstructured":"Zollner G, Marschall H-U, Wagner M et al (2006) Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 3:231\u2013251","journal-title":"Mol Pharm"},{"issue":"Suppl 1","key":"12_CR47","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1038\/modpathol.3800680","volume":"20","author":"EM Brunt","year":"2007","unstructured":"Brunt EM (2007) Pathology of fatty liver disease. Mod Pathol 20(Suppl 1):S40\u2013S48","journal-title":"Mod Pathol"},{"issue":"10","key":"12_CR48","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.2174\/138920012803762765","volume":"13","author":"M Cherkaoui-Malki","year":"2012","unstructured":"Cherkaoui-Malki M, Surapureddi S, El Hajj HI, Vamecq J et al (2012) Hepatic steatosis and peroxisomal fatty acid beta-oxidation. Curr Drug Metab 13(10):1412\u20131421","journal-title":"Curr Drug Metab"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.abb.2010.09.001","volume":"504","author":"Y Kawano","year":"2010","unstructured":"Kawano Y, Nishiumi S, Tanaka S et al (2010) Activation of the aryl hydrocarbon receptor induces hepatic steatosis via the upregulation of fatty acid transport. Arch Biochem Biophys 504:221\u2013227","journal-title":"Arch Biochem Biophys"},{"key":"12_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109609","volume":"121","author":"Y Xi","year":"2020","unstructured":"Xi Y, Li H (2020) Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Biomed Pharmacother 121:109609","journal-title":"Biomed Pharmacother"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"25776","DOI":"10.1074\/jbc.M116.752311","volume":"291","author":"JS Marino","year":"2016","unstructured":"Marino JS, Stechschulte LA, Stec DE et al (2016) Glucocorticoid receptor \u03b2 induces hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor (PPAR) \u03b1. J Biol Chem 291:25776\u201325788","journal-title":"J Biol Chem"},{"key":"12_CR52","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.3748\/wjg.v28.i48.6909","volume":"28","author":"VN Bukke","year":"2022","unstructured":"Bukke VN, Moola A, Serviddio G et al (2022) Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease. World J Gastroenterol 28:6909\u20136921","journal-title":"World J Gastroenterol"},{"key":"12_CR53","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1124\/dmd.106.010645","volume":"34","author":"J Sugatani","year":"2006","unstructured":"Sugatani J, Wada T, Osabe M et al (2006) Dietary inulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet: association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4alpha expression. Drug Metab Dispos 34:1677\u20131687","journal-title":"Drug Metab Dispos"},{"key":"12_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2021.105269","volume":"79","author":"SE Escher","year":"2022","unstructured":"Escher SE, Aguayo-Orozco A, Benfenati E et al (2022) Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action. Toxicol In Vitro 79:105269","journal-title":"Toxicol In Vitro"},{"key":"12_CR55","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/10408444.2015.1089471","volume":"46","author":"CL Mellor","year":"2016","unstructured":"Mellor CL, Steinmetz FP, Cronin MTD (2016) The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Crit Rev Toxicol 46:138\u2013152","journal-title":"Crit Rev Toxicol"},{"key":"12_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tox.2017.11.013","volume":"393","author":"SGJ Breda","year":"2018","unstructured":"Breda SGJ, Claessen SMH, Herwijnen M et al (2018) Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology 393:160\u2013170","journal-title":"Toxicology"},{"key":"12_CR57","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E et al (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62:1148\u20131155","journal-title":"J Hepatol"},{"key":"12_CR58","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","volume":"16","author":"EM Brunt","year":"2010","unstructured":"Brunt EM, Tiniakos DG (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16:5286\u20135296","journal-title":"World J Gastroenterol"},{"key":"12_CR59","first-page":"1133","volume":"242","author":"J Geneve","year":"1987","unstructured":"Geneve J, Hayat-Bonan B, Labbe G et al (1987) Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 242:1133\u20131137","journal-title":"J Pharmacol Exp Ther"},{"key":"12_CR60","first-page":"529","volume":"255","author":"E Freneaux","year":"1990","unstructured":"Freneaux E, Fromenty B, Berson A et al (1990) Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J Pharmacol Exp Ther 255:529\u2013535","journal-title":"J Pharmacol Exp Ther"},{"key":"12_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","volume":"6","author":"K Begriche","year":"2006","unstructured":"Begriche K, Igoudjil A, Pessayre D et al (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6:1\u201328","journal-title":"Mitochondrion"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","volume":"19","author":"S-H Koo","year":"2013","unstructured":"Koo S-H (2013) Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 19:210\u2013215","journal-title":"Clin Mol Hepatol"},{"key":"12_CR63","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5604\/16652681.1171749","volume":"14","author":"SK Satapathy","year":"2015","unstructured":"Satapathy SK, Kuwajima V, Nadelson J et al (2015) Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol 14:789\u2013806","journal-title":"Ann Hepatol"},{"key":"12_CR64","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.matbio.2017.12.012","volume":"68\u201369","author":"E Roeb","year":"2018","unstructured":"Roeb E (2018) Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol 68\u201369:463\u2013473","journal-title":"Matrix Biol"},{"key":"12_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","volume":"25","author":"UE Lee","year":"2011","unstructured":"Lee UE, Friedman SL (2011) Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25:195\u2013206","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"12_CR66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ncpgasthep0055","volume":"1","author":"SL Friedman","year":"2004","unstructured":"Friedman SL (2004) Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1:98\u2013105","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"12_CR67","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","volume":"134","author":"V Krizhanovsky","year":"2008","unstructured":"Krizhanovsky V, Yon M, Dickins RA et al (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 134:657\u2013667","journal-title":"Cell"},{"key":"12_CR68","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00204-016-1814-8","volume":"91","author":"T Horvat","year":"2017","unstructured":"Horvat T, Landesmann B, Lostia A et al (2017) Adverse outcome pathway development from protein alkylation to liver fibrosis. Arch Toxicol 91:1523\u20131543","journal-title":"Arch Toxicol"},{"key":"12_CR69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13578-017-0188-9","volume":"7","author":"Y Cao","year":"2017","unstructured":"Cao Y (2017) Tumorigenesis as a process of gradual loss of original cell identity and gain of properties of neural precursor\/progenitor cells. Cell Biosci 7:61","journal-title":"Cell Biosci"},{"key":"12_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"12_CR71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","volume":"152","author":"D Sia","year":"2017","unstructured":"Sia D, Villanueva A, Friedman SL et al (2017) Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 152:745\u2013761","journal-title":"Gastroenterology"},{"key":"12_CR72","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/carcin\/bgn155","volume":"29","author":"DF Calvisi","year":"2008","unstructured":"Calvisi DF, Pinna F, Ladu S et al (2008) Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 29:1639\u20131647","journal-title":"Carcinogenesis"},{"key":"12_CR73","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/carcin\/bgh285","volume":"26","author":"T Hays","year":"2005","unstructured":"Hays T, Rusyn I, Burns AM et al (2005) Role of peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26:219\u2013227","journal-title":"Carcinogenesis"},{"key":"12_CR74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.dnarep.2019.03.004","volume":"77","author":"AK McCullough","year":"2019","unstructured":"McCullough AK, Lloyd RS (2019) Mechanisms underlying aflatoxin-associated mutagenesis \u2013 implications in carcinogenesis. DNA Repair (Amst) 77:76\u201386","journal-title":"DNA Repair (Amst)"},{"key":"12_CR75","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1248\/bpb.b19-00267","volume":"42","author":"K Yoshinari","year":"2019","unstructured":"Yoshinari K (2019) Role of nuclear receptors PXR and CAR in xenobiotic-induced hepatocyte proliferation and chemical carcinogenesis. Biol Pharm Bull 42:1243\u20131252","journal-title":"Biol Pharm Bull"},{"key":"12_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2020.12.007","volume":"73","author":"J Font-D\u00edaz","year":"2021","unstructured":"Font-D\u00edaz J, Jim\u00e9nez-Panizo A, Caelles C et al (2021) Nuclear receptors: lipid and hormone sensors with essential roles in the control of cancer development. Semin Cancer Biol 73:58\u201375","journal-title":"Semin Cancer Biol"},{"key":"12_CR77","unstructured":"Webster F, Lambert IB, and Yauk CL (2021) Adverse outcome pathway on Cyp2E1 activation leading to liver cancer"},{"key":"12_CR78","unstructured":"Four Steps of Risk assessment \u2013 EFSA. https:\/\/multimedia.efsa.europa.eu\/riskassessment\/index.htm"},{"key":"12_CR79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/toxsci\/kfv181","volume":"148","author":"EJ Perkins","year":"2015","unstructured":"Perkins EJ, Antczak P, Burgoon L et al (2015) Adverse outcome pathways for regulatory applications: examination of four case studies with different degrees of completeness and scientific confidence. Toxicol Sci 148:14\u201325","journal-title":"Toxicol Sci"},{"key":"12_CR80","unstructured":"OECD (2017) Guidance document for the use of adverse outcome pathways in developing integrated approaches to testing and assessment (IATA)"},{"key":"12_CR81","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00204-017-2020-z","volume":"91","author":"M Vinken","year":"2017","unstructured":"Vinken M, Knapen D, Vergauwen L et al (2017) Adverse outcome pathways: a concise introduction for toxicologists. Arch Toxicol 91:3697\u20133707","journal-title":"Arch Toxicol"},{"key":"12_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-1-4939-7899-1_2","volume-title":"Computational toxicology: methods and protocols","author":"TW Schultz","year":"2018","unstructured":"Schultz TW, Diderich R, Kuseva CD et al (2018) The OECD QSAR toolbox starts its second decade. In: Nicolotti O (ed) Computational toxicology: methods and protocols. Springer, New York, pp 55\u201377"},{"key":"12_CR83","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1124\/dmd.112.047068","volume":"40","author":"DJ Warner","year":"2012","unstructured":"Warner DJ, Chen H, Cantin L-D et al (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab Dispos 40:2332\u20132341","journal-title":"Drug Metab Dispos"},{"key":"12_CR84","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1208\/s12248-009-9137-9","volume":"11","author":"H Saito","year":"2009","unstructured":"Saito H, Osumi M, Hirano H et al (2009) Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11\/BSEP). AAPS J 11:581","journal-title":"AAPS J"},{"key":"12_CR85","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1023\/A:1011064806507","volume":"18","author":"YH Han","year":"2001","unstructured":"Han YH, Kato Y, Haramura M et al (2001) Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT\/MRP2). Pharm Res 18:579\u2013586","journal-title":"Pharm Res"},{"key":"12_CR86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejps.2017.02.005","volume":"103","author":"G Wissel","year":"2017","unstructured":"Wissel G, Deng F, Kudryavtsev P et al (2017) A structure-activity relationship study of ABCC2 inhibitors. Eur J Pharm Sci 103:60\u201369","journal-title":"Eur J Pharm Sci"},{"key":"12_CR87","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1208\/s12248-009-9117-0","volume":"11","author":"L Xing","year":"2009","unstructured":"Xing L, Hu Y, Lai Y (2009) Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions. AAPS J 11:406\u2013413","journal-title":"AAPS J"},{"key":"12_CR88","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1874104500802010087","volume":"2","author":"KM Hon\u00f3rio","year":"2008","unstructured":"Hon\u00f3rio KM, Salum LB, Garratt RC et al (2008) Two- and three-dimensional quantitative structure-activity relationships studies on a series of liver x receptor ligands. Open Med Chem J 2:87\u201396","journal-title":"Open Med Chem J"},{"key":"12_CR89","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1021\/acs.jcim.8b00297","volume":"58","author":"D Gadaleta","year":"2018","unstructured":"Gadaleta D, Manganelli S, Roncaglioni A et al (2018) QSAR modeling of ToxCast assays relevant to the molecular initiating events of AOPs leading to hepatic steatosis. J Chem Inf Model 58:1501\u20131517","journal-title":"J Chem Inf Model"},{"key":"12_CR90","doi-asserted-by":"publisher","unstructured":"Abdelaziz A, Spahn-Langguth H, Schramm K-W et al (2016) Consensus modeling for HTS assays using in silico descriptors calculates the best balanced accuracy in Tox21 challenge. Front Environ Sci. https:\/\/doi.org\/10.3389\/fenvs.2016.00002","DOI":"10.3389\/fenvs.2016.00002"},{"key":"12_CR91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.comtox.2017.01.001","volume":"1","author":"SA Rosenberg","year":"2017","unstructured":"Rosenberg SA, Xia M, Huang R et al (2017) QSAR development and profiling of 72,524 REACH substances for PXR activation and CYP3A4 induction. Comput Toxicol 1:39\u201348","journal-title":"Comput Toxicol"},{"key":"12_CR92","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.yrtph.2015.02.011","volume":"71","author":"G Patlewicz","year":"2015","unstructured":"Patlewicz G, Simon TW, Rowlands JC et al (2015) Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. Regul Toxicol Pharmacol 71:463\u2013477","journal-title":"Regul Toxicol Pharmacol"},{"key":"12_CR93","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1007\/s00204-019-02591-7","volume":"93","author":"SE Escher","year":"2019","unstructured":"Escher SE, Kamp H, Bennekou SH et al (2019) Towards grouping concepts based on new approach methodologies in chemical hazard assessment: the read-across approach of the EU-ToxRisk project. Arch Toxicol 93:3643\u20133667","journal-title":"Arch Toxicol"},{"key":"12_CR94","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1021\/acs.chemrestox.5b00208","volume":"28","author":"M Vinken","year":"2015","unstructured":"Vinken M (2015) Adverse outcome pathways and drug-induced liver injury testing. Chem Res Toxicol 28:1391\u20131397","journal-title":"Chem Res Toxicol"},{"key":"12_CR95","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3109\/10408444.2013.811215","volume":"43","author":"M Hewitt","year":"2013","unstructured":"Hewitt M, Enoch SJ, Madden JC et al (2013) Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. Crit Rev Toxicol 43:537\u2013558","journal-title":"Crit Rev Toxicol"},{"key":"12_CR96","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.taap.2018.07.023","volume":"356","author":"J Rooney","year":"2018","unstructured":"Rooney J, Hill T, Qin C et al (2018) Adverse outcome pathway-driven identification of rat liver tumorigens in short-term assays. Toxicol Appl Pharmacol 356:99\u2013113","journal-title":"Toxicol Appl Pharmacol"},{"key":"12_CR97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tiv.2018.09.002","volume":"54","author":"NO Oki","year":"2019","unstructured":"Oki NO, Farcal L, Abdelaziz A et al (2019) Integrated analysis of in vitro data and the adverse outcome pathway framework for prioritization and regulatory applications: an exploratory case study using publicly available data on piperonyl butoxide and liver models. Toxicol In Vitro 54:23\u201332","journal-title":"Toxicol In Vitro"},{"key":"12_CR98","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00204-021-03182-1","volume":"96","author":"J Alarcan","year":"2022","unstructured":"Alarcan J, de Sousa G, Katsanou ES et al (2022) Investigating the in vitro steatotic mixture effects of similarly and dissimilarly acting test compounds using an adverse outcome pathway-based approach. Arch Toxicol 96:211\u2013229","journal-title":"Arch Toxicol"},{"key":"12_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111283","volume":"139","author":"D Lichtenstein","year":"2020","unstructured":"Lichtenstein D, Luckert C, Alarcan J et al (2020) An adverse outcome pathway-based approach to assess steatotic mixture effects of hepatotoxic pesticides in vitro. Food Chem Toxicol 139:111283","journal-title":"Food Chem Toxicol"},{"key":"12_CR100","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.comtox.2019.01.004","volume":"10","author":"A Palczewska","year":"2019","unstructured":"Palczewska A, Kovarich S, Ciacci A et al (2019) Ranking strategies to support toxicity prediction: a case study on potential LXR binders. Comput Toxicol 10:130\u2013144","journal-title":"Comput Toxicol"},{"key":"12_CR101","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12302-019-0195-z","volume":"31","author":"L Bajard","year":"2019","unstructured":"Bajard L, Melymuk L, Blaha L (2019) Prioritization of hazards of novel flame retardants using the mechanistic toxicology information from ToxCast and adverse outcome pathways. Environ Sci Eur 31:14","journal-title":"Environ Sci Eur"},{"key":"12_CR102","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/risa.13423","volume":"40","author":"LD Burgoon","year":"2020","unstructured":"Burgoon LD, Angrish M, Garcia-Reyero N et al (2020) Predicting the probability that a chemical causes steatosis using adverse outcome pathway Bayesian networks (AOPBNs). Risk Anal 40:512\u2013523","journal-title":"Risk Anal"},{"key":"12_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102500","volume":"4","author":"M Karaca","year":"2023","unstructured":"Karaca M, Fritsche K, Lichtenstein D et al (2023) Adverse outcome pathway-based analysis of liver steatosis in vitro using human liver cell lines. STAR Protoc 4:102500","journal-title":"STAR Protoc"},{"key":"12_CR104","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/toxsci\/kfaa101","volume":"177","author":"JC Corton","year":"2020","unstructured":"Corton JC, Hill T, Sutherland JJ et al (2020) A set of six gene expression biomarkers identify rat liver Tumorigens in short-term assays. Toxicol Sci 177:11\u201326","journal-title":"Toxicol Sci"},{"key":"12_CR105","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s00204-023-03583-4","volume":"97","author":"J Jiang","year":"2023","unstructured":"Jiang J, van Ertvelde J, Ertaylan G et al (2023) Unraveling the mechanisms underlying drug-induced cholestatic liver injury: identifying key genes using machine learning techniques on human in vitro data sets. Arch Toxicol 97:2969\u20132981","journal-title":"Arch Toxicol"},{"key":"12_CR106","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s00204-017-2045-3","volume":"91","author":"M Leist","year":"2017","unstructured":"Leist M, Ghallab A, Graepel R et al (2017) Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol 91:3477\u20133505","journal-title":"Arch Toxicol"},{"key":"12_CR107","unstructured":"(2020) OECD | Overview of Concepts and Available Guidance related to Integrated Approaches to Testing and Assessment (IATA), OECD Series on Testing and Assessment, No. 329, Environment, Health and Safety, Environment Directorate, OECD"},{"key":"12_CR108","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1021\/acs.est.6b06230","volume":"51","author":"RB Conolly","year":"2017","unstructured":"Conolly RB, Ankley GT, Cheng W et al (2017) Quantitative adverse outcome pathways and their application to predictive toxicology. Environ Sci Technol 51:4661\u20134672","journal-title":"Environ Sci Technol"},{"key":"12_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2020.104855","volume":"66","author":"RA Clewell","year":"2020","unstructured":"Clewell RA, Leonard JA, Nicolas CI et al (2020) Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: a case study with phthalates. Toxicol In Vitro 66:104855","journal-title":"Toxicol In Vitro"},{"key":"12_CR110","first-page":"659","volume":"29","author":"M Vinken","year":"2020","unstructured":"Vinken M (2020) Liver adverse outcome pathways: what\u2019s in for the hepatologist? J Gastrointestin Liver Dis 29:659\u2013664","journal-title":"J Gastrointestin Liver Dis"},{"key":"12_CR111","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.drudis.2016.10.011","volume":"22","author":"GR Langley","year":"2017","unstructured":"Langley GR, Adcock IM, Busquet F et al (2017) Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug Discov Today 22:327\u2013339","journal-title":"Drug Discov Today"}],"container-title":["Methods in Molecular Biology","Computational Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4003-6_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T06:04:13Z","timestamp":1727071453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4003-6_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"ISBN":["9781071640029","9781071640036"],"references-count":111,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4003-6_12","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-0716-4003-6","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"24 September 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}